The Swiss drugmaker Novartis AG has won approval for it’s eagerly awaited heart medication Entresto sooner than expected and thus raising hopes for a medicine that has been analysts for reaping billions of dollars in annual sales. Initially the approval was supposed to be received in August.
The U.S. Food and Drug Administration has stated that the drug has demonstrated to cut down cardiovascular death and hospitalization that is related to associated to health failure along with helping patients live a much longer and active life.
Entresto, also called LCZ696 is the first new drug that developed in decades that helps patients who are in danger as their hearts are unable to pump blood in an efficient manner. Therefore, it is expected to be one the biggest new drug that launched in 2015.
It has been forecasted from the analysts in the industry that by 2020 the annual sales may hit $4.4 billion. While another major product of Novartis, the blood pressure pill Diovan are facing fierce competition from generics, the company is looking to perk up some of its fortune from Entresto.
The drug is going to be priced at $12.50 a day at the wholesale level and according to Novartis it has parallel pricing with other new cardiovascular treatments. The drug will also be competing with other very cheap, although less effective pills and Novartis has warned that initial uptake may be slow.
Novartis’ head of pharmaceuticals, David Epstein has said that he has talked to healthcare customers about a system which would help sell the drug at a discounted rate and eventually pay Novartis more when the drug helps to effectively lower expensive hospital bills, which it eventually will.
The pricing issue has come to a head not too long ago but because of the launch of extremely expensive new medication for Hepatitis C and cancer, that are injuring healthcare systems along with adding up chunks of co-payment costs for patients.
About 5.1 million people in the U.S. alone are affected by heart failure and about 50% of them have the reduced ejection failure form for where the heart muscle fails to contract effectively, Entresto has been proven to be very suitable.
The possible side effects that come with such intense medication include low blood pressure, poor kidney function and high blood potassium levels. Entresto is actually two-in-one pill, that needs to be popped twice every day with a blend of Diovan’s active ingredient valsartan and another class of drug known as neprilysin inhibitor.
